| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/28/2023 | 18.61% | Piper Sandler | $30 → $32 | Maintains | Neutral |
| 04/27/2023 | 11.19% | Piper Sandler | $36 → $30 | Maintains | Neutral |
| 04/20/2023 | 0.07% | Wedbush | $37 → $27 | Maintains | Neutral |
| 02/23/2023 | 26.02% | UBS | $31 → $34 | Maintains | Neutral |
| 02/23/2023 | 37.14% | Wedbush | $27 → $37 | Maintains | Neutral |
| 02/02/2023 | 29.73% | Piper Sandler | $26 → $35 | Maintains | Neutral |
| 07/28/2022 | 40.85% | UBS | $40 → $38 | Maintains | Neutral |
| 06/14/2022 | 48.26% | Piper Sandler | $49 → $40 | Maintains | Neutral |
| 04/21/2022 | 81.62% | Piper Sandler | $62 → $49 | Downgrades | Overweight → Neutral |
| 04/18/2022 | 66.79% | B of A Securities | $55 → $45 | Maintains | Underperform |
| 04/07/2022 | 129.8% | Piper Sandler | $75 → $62 | Maintains | Overweight |
| 03/28/2022 | 100.15% | Wedbush | → $54 | Downgrades | Outperform → Neutral |
| 02/24/2022 | 140.92% | UBS | $80 → $65 | Maintains | Neutral |
| 02/04/2022 | 226.17% | Wedbush | $85 → $88 | Upgrades | Neutral → Outperform |
| 02/18/2021 | 511.56% | Piper Sandler | $108 → $165 | Maintains | Overweight |
| 02/10/2021 | 344.77% | Wedbush | $52 → $120 | Maintains | Neutral |
| 02/04/2021 | 226.17% | B of A Securities | → $88 | Downgrades | Neutral → Underperform |
| 11/17/2020 | 170.57% | B of A Securities | → $73 | Upgrades | Underperform → Neutral |
| 10/15/2020 | 63.08% | B of A Securities | $31 → $44 | Maintains | Underperform |
| 07/10/2020 | 140.92% | Piper Sandler | $39 → $65 | Upgrades | Neutral → Overweight |
| 04/23/2020 | 7.49% | Piper Sandler | $28 → $29 | Maintains | Neutral |
| 04/15/2020 | 3.78% | Piper Sandler | $62 → $28 | Maintains | Neutral |
| 04/13/2020 | 11.19% | Wedbush | $25 → $30 | Maintains | Neutral |
| 03/30/2020 | -33.28% | UBS | $34 → $18 | Maintains | Sell |
| 03/25/2020 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 02/20/2020 | 118.68% | Wedbush | $45 → $59 | Maintains | Neutral |
| 02/20/2020 | 22.31% | B of A Securities | $30 → $33 | Reiterates | → Underperform |
| 02/20/2020 | 26.02% | UBS | $31 → $34 | Maintains | Sell |
| 02/20/2020 | 129.8% | Raymond James | $54 → $62 | Maintains | Outperform |
| 10/16/2019 | 7.49% | UBS | $27 → $29 | Maintains | Sell |
| 10/16/2019 | 81.62% | Piper Sandler | $43 → $49 | Maintains | Neutral |
| 10/16/2019 | 66.79% | Wedbush | $44 → $45 | Maintains | Neutral |
| 10/09/2019 | 77.91% | Raymond James | → $48 | Upgrades | Market Perform → Outperform |
| 09/23/2019 | 11.19% | B of A Securities | $34 → $30 | Maintains | Underperform |
| 01/28/2019 | 33.43% | Barclays | → $36 | Initiates Coverage On | → Equal-Weight |
What is the target price for Sleep Number (SNBR)?
The latest price target for Sleep Number (NASDAQ: SNBR) was reported by Piper Sandler on July 28, 2023. The analyst firm set a price target for $32.00 expecting SNBR to rise to within 12 months (a possible 18.61% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sleep Number (SNBR)?
The latest analyst rating for Sleep Number (NASDAQ: SNBR) was provided by Piper Sandler, and Sleep Number maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Sleep Number (SNBR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sleep Number, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sleep Number was filed on July 28, 2023 so you should expect the next rating to be made available sometime around July 28, 2024.
Is the Analyst Rating Sleep Number (SNBR) correct?
While ratings are subjective and will change, the latest Sleep Number (SNBR) rating was a maintained with a price target of $30.00 to $32.00. The current price Sleep Number (SNBR) is trading at is $26.98, which is out of the analyst's predicted range.